>PROKKA_00001 Clostridium P-47 protein
MQTTTLNWDTVYAVPINIVNEAIKLKHPTPENFELLNGKYGNCSGSFEDWQITNGGDGSN
IRLKIPIKNFKATIIGNRLNGKGGFAFANLEVQVKLKYLPHFPQSKNKNIELVDLKIRTQ
SDNPEDPAIIVISSYKNIQGFYFEDEYKLTEDDEFVASYFYRLIKEWLEKNLHFFNYIFN
TVNLNLYISDKEKWEWTKPSYVDYAYSEIEGDLSKSALGVLCMTGGRTGSKNQQQKIDPY
AIPKKSQSGFLISEERLLRNILLPTIPKKFPKSKGDEFEVINESSQGGGYSYILKLKKGK
KIDLENIQAVGYTCTPYIQEMKIYLLGSYLKLETTTRVDLPLGVASICETTCEYKFKLST
NNKGEQTIAYEQIGSPVNIQYSENTGNVGLNIVVSFLSATLSFALTFVPGFGTFLAVGLI
GGCLIGSVALIPTFIESYNSDTAPSIDLSLENSVSEITWNSSDVFNLDYVALAGPLQLGG
TLQVQNS*
>PROKKA_00002 Clostridium P-47 protein
MKKIYYKFHKGGILMTNLKPYIIYDWKETILKNSKDNYYINESIPKTFSKKICGGRFFNS
TLSGNWKSWTLTDEGEGPHPVLKCTIDNGYLEIYSNTFSEKHSLKDIEIKVCMSIKPNSD
GTHSLCKNSFYIKNNSLKLSEDRLIVSHCLDKLILAWFKDNHKYIELFINRSRIQTRVEG
DLSLLGWDIESSVSYKTMNEFIKKDNLYEKKFYESVTFRKMKVTIDGEFGPWQMTTGADG
RNIRFLCPIKSATYKIDEDVYIAKPDNFIIIQVDLKYFDSKTTITDPSGLNNGQQLNLKI
KTDSTDEIDAVILVGSKITDVNDGFIEGDDVYLEIVFRTWFNNNIQKFTQIFSYILLNET
SKIPEYQWLKPTQISYGSASVTMPDPSNPNKELSNLDASTFAAMAMVENHKNDRPNHAVD
NRFLELSKTPAAFAISMPEFLKHFLVTGLQAMQIDNLDAFEVSSENLVITNKKKINFGKI
QDQNRQVDALIEPNNFKLAIQNNQVVVEIVDATWQQVVGVTGHFGYRQAYNLILKNENNV
YKPMLEESGDVTISYMVTEEAWKTTQDAIISATVGLVVGTIIGTAFSKLSDKLYKFLKSK
FIVKNKKASLKISGKDINEVIEMSDLSKPQLLSIKKANAKISTEEVGLISKNGSTSLENL
ALFKNKPRPIGERVQILGLKLVSGLITTFGLSIGFVLPDILKDVINANINNDFEVLPGIQ
QFTQQCIGSIQWPDNSELKIDFAKLQGVYLLGGNLVKIPESN*
>PROKKA_00003 hypothetical protein
MELKQAFVFEFDENLSSSSGSIHLEKVKQNCSPNYDYFKITFIDGYLYIKNKSGVILDKY
DLKNVISLVALKRDYLSLSLSNNKQIKKFKNIKNKHLKNKFNLYVINEDIEKRITKNGIL
EEVILNKMLLSILLGNEENLLQIS*
>PROKKA_00004 Clostridium P-47 protein
MNTYGWDIVYGCSNMVVNKHLKNYIDENRIEFLYSDINKKEEIKMIFDNWEIINGGTSNF
LRIKIFIKEGYFKFRNTTVDLSGVIPILEIKLDFFNDASNPYIKKLKFSFGNKTNDNIKV
IVSDLSGKLYEEDEFYFNKLLISAFINNEKQVSYIFASLNVTSNIVWMNPKQFKFVYYSP
TDNSDGYLCILSVVTNRDISKLSTNVDSSILSENSEVGLLISEKLFMENLVLPKLSSNMG
SNITSNNFNVINTSDTTGIIKNKNTLNWYGIKVAALYYYPEINDFSMELFEGNKLKTRLS
GIVKLTGYERIYSKLNMECITKFIYDNKNKKVSFEIYSTPIMECRPIFGLLDGIPAAVAK
SVGNWSLKSFRDSLAFELANNFTDIINDIVNWNNLKISEVTNIILNVGFCIQGNMN*
>PROKKA_00005 Botulinum neurotoxin type E precursor
MKINGNLNIYSPVDNKNVAIVRSRKSDVFFKAFQVAPNIWIVPERYYGESLNINEDQKSD
GGIYDSNFLSTNNEKDEFLQATIKLLQRINNNVVGAKLLSLISTAIPFLYENNTEDYRQT
NYLSSKNNEHYYTANLVIFGPGSNIIKNNVIYYKKEYAENGMGTMLEIWFQPFLTYKYDE
FYVDPALELIKCLIKSLYYLYGIKPNDNLNIPYRLRNEFNSLEYSELDMMDFLISGGIDY
KLLNTNPYWFIDKYFIDTSKNFEKYKNDYEIKIKNNNYIANSIKLYLEQKFKINVKDIWE
LNLSYFSKEFQIMMPERYNNALNHYYRKEYYVIDYCKNYNINGFKNGQIKTKLPLSKYNK
EIINKPELIFNLINQNNTVLMKSNIYGDGLKGTVDNFYSNYIIPYNLNYEHSINYSYLDN
VNIEEIEKIPPINDEDIYPYRKNADTFIPVYNITKAKEINTTTPLPVNYLQAQMIDSNDI
NLSSDFLKVISSKGSLVYSFLNNTMDYLEFIKYDKPIDTDKKYYKWLKAIFRNYSLDITE
TQEISNQFGDTKIIPWIGRALNILNTNNSFVEEFKNLGPISLINKKENITIPKIKIDEIP
SSMLNFSFKDLSENLFNIYCKNNFYLKKIYYNFLDQWWTQYYSQYFDLICMASKSVLAQE
KLIKKLIQKQLRYLMENSNISSTNLILINLTTTNTLRDISNQSQIAINNIDKFFNNAAMC
VFENNIYPKFTSFMEQCIKNINKSTKEFILKCTNINETEKSHLIMQNSFSNLDFDFLDIQ
NMKNLFNSYTELLIKEQTSPYELSLYAFQEQDNNVIGDTSGKNTLVEYPKDIGLVYGINN
NAIHLTGANQNIKFTNDYFENGLTNNFSIYFWLRNLNQNTIKSKLIGSKEDNCGWEIYFE
NDGLVFNIIDSNGNEKNIYLSNISNNSWHYIVISINRLKDQLLIFIDNILVANEDIKEIL
NIYSSDIISLLSDNNNVYIEGLSVLNKTINSNEILTDYFSDLNNSYIRNFDEEILQYNRT
YELFNYVFPEIAINKIEQNNNIYLSINNENNLNFKPLKFKLLNTNPNKQYVQKWDEVIFS
VLDGTEKYLDISTTNNRIQLVDNKNNAKIFIINNYIFISNCLTLTYNNVNVYLSIKNQDY
NWVICDLNHDIPKKSYLWILKNI*
>PROKKA_00006 Botulinum neurotoxin type E precursor
MPKINSFNYNDPVNDKTILYIKPGGCQQFYKSFNIMKNIWIIPERNVIGTIPQDFLPPTS
LKNGDSSYYDPNYLQSNEEKDRFLKIVTKIFNRINDNLSGGILLEELSKANPYLGNDNTP
NNQFHIGDASAVEIKFSNGSQSILLPTVIIMGAEPDLFETNSSNISLKNNYMPSNHGFGS
IAIVTFSPEYSFRFNDNSMNEFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQQQNPL
ITNIRGTNIEEFLTFGGTDLNIITNAQSNDIYTNLLADYKKIASKLSQVQVSNPQLNPYK
DIFQEKYGLDKNASGIYSVNINKFDDIFKKLYSFTEFDLATKFQVKCRQTYIGQYKYFKL
SNLLNNSIYNISEGYNINTLKVNFRGQNTNLNPRIITQLTGRGLVKKIIRFCKNIVFSKG
ITKSICIEINNGELFFVASENSYNDDNINTPKEIDDTVTSNNNYENDLDQVILNFNSESA
PGLSDEKLNLTIQNDAYIPKYDSNGTSDIEQHDVNELNVFFYLDAQKVPEGENNVNLTSS
IDTALLEQPKIYTFFSSEFINNVNKPVQAALFVSWIQQVLVDFTTEANQKSTVDKIADIS
IVVPYIGLALNIGNEAQKGNFKDALELLGAGILLEFEPELLIPTILVFTIKSFLGSSDNK
NKVIKAINNALKERDEKWKEVYSFIVSNWMTKINTQFNKRKEQMYQALQNQVNALKTIIE
SKYNSYTLEEKNELTNKYNIEQIENELNQKVSIAMNNIEIFLTESSISYLMKLINEVKIN
KLREYDENVKTYLLDYIIKHGSILGESQQELNSMVIDTLNNSIPFKLSSYTDDKILISYF
NKFFKRIKSSSVLNMRYKNDKYVDTSGYDSNININGDVYKYPTNKNQFGIYNDKLSEVNI
SQNDYIIYDNKYKNFSISFWVRIPNYDNKIVNVNNEYTIINCMRDNNSGWKVSLNHNEII
WTLQDNAGINQKLAFNYGNANGISDYINKWIFVTITNDRLGDSKLYINGNLIDKKSILNL
GNIHVSDNILFKIVNCSYTRYIGMRYFNIFDKELDKTEIETLYNNEPNTNILKDFWGNYL
LYDKEYYLLNVLKPNNVIDSNRDSTFSIHNIRSTIVLANKLYLGIKVKIQRVNNSSTNDN
LVRKNDQVYINFVPIKTHLFPLYADTNTTNKEKTIKSSSSGNRFNQVVVMNSVGNNCTMN
FKNNNGNNIGMLGFKDNTLVASTWYYTHMRDNTNSNGCFWNFISEEHGWQEK*
>PROKKA_00007 Helix-turn-helix domain protein
MNRNIIGKKVRIIRKAKNLTQEELIVRIQLKGLNINRPMLSRIETDSREVYDFKVKAIAE
ALDISVDELFIQN*
>PROKKA_00008 Replication-associated recombination protein A
MTPLAERMRPTKLEDFVGQKQIIGEGKPLYNIIKSKNIVNCILYGPPGTGKTTLANIMAN
YVDRKFYKLNATTASVKDIQEIASSLDTLLGYNGVVVYIDELQHFSKKQQQSLLEFIEKG
QITLIASTTENPYFVLHKAILSRCNIFTFKPLTTDDIKFGVVKAIERAIENGMEIKYTDD
AISYIAEISQGDYRKAYNILELGIISSLKRTLEITVEYIEELEQSHIRFDASGDEFYNSL
SALQKSIRGSDADAAIHYLARLTKSGNLTAIVRRLGVIVAEDIGLAHPNALTVVNSGLEL
VLKVGLPEAQLILSELVIYLATLPKSNSAYLAIKSAMQDLENKNVGDVPVHLKDAHYSSA
QKLGVGGYKYPHDYSNNYVKQKYMPQELRDTIYYIPQENKYEGSIKNYWKNIKE*
>PROKKA_00009 hypothetical protein
MGKVGRKENCNISDNDMLVALERYTREFPNEKINIKKLADFSGIERHYWYSRKGFREKIE
EINSISYEKYDIISDGDRKKIKFPNVDEVVDNNFRNKKRLKFILNSFFLTYQDFYESSCE
AYKLKKDINILKDKIIKYEDEIQKLKNERDKFRELSNYNENKYYEIAIRSRERNFRKENN
IKSNVIEINNKNIKAYSTDEDDLDSLLNRIDD*
>PROKKA_00010 hypothetical protein
MNNKQQYKLALREGLLVNQIANNSDSLVIVTKELKIYKEEELDYYKEKFNYFKKKGRIVN
CVFNDLIWTLSETDEGGYKSNRNIKFSINFINKNNIIKAYLINLLINLININTIVERVRV
VSDIINISNFFDIDKFNEFEEYIESTFDNNKLNMKDYTMNFISFIRDNVDEEYCNYLVSL
PNEYFSKTREIPDYTSILKFDFLLDKYLKNSDEKEFFRYYPIVLWWKICSKIPLRPCEFM
ILKKDCVYEKNRKYYIRIRRCKPHGFVNKALNIRKEQSFRINKEIYDLVMKVVSHKSHDC
EFLLSKNLYNKYYTQYTYKEELVQGRVMRSYNLDKCLKDFYYYEINNKNIQTVISKKDVK
ESLSQQFYRDCMVSLQLGDARHLAIINLVLQGTNSYLIREMCGHRDINSHLHYIDHAKTY
ITSKVLVLTDIRKLEIKLANIYSNESFEYGNKRNNKVSNLLYNEYKKVGDIYCKRYVGRK
EMFPFLCLTDCDECNDKVETDFTGNTDEEIKTNKMEIERQFQIIEKYLKDAQFNSIIDSK
NERVLFESQKNIEESANKLNYLISKEAELEAKIFFGGMITKEE*
>PROKKA_00011 hypothetical protein
VIELEDAAKEINPKCYKYFMKKLKTLNNINIFDKNGKLFITKNDFEKLKRNKASKIPYHI
DIPNGYASRNEAVKKYNINYNSLRHNEEKGIIKTAISGGIAFLEKESIEKHIEFLKYIEK
INNDDNWIKVSSLRGKPYYDRISYTVRRNDFKNDLIKIGIGRTAEFFITRKLYKEIINGK
HKIIVTSQHKKKILKDDIEGIITKLLIETGVNSIRQKAKMKQLIKVKEISELSGIDYEEI
IESRRYFNGEIVKEQNIEYMHRYDIENIMKNFGYYSIKKLSKICGISFSTLIRDFNIANF
LGIYINFKIDKDFFVDINGVEIILKEFSKNYIATLTLDEIYRERMKLFPDEFFKTYKLAD
EFIVKKKRNCYRPYGEDTTSYNRVINSIENLVNYLDKEIFEYSAEELLKLVSNTNIVKRG
YQAHVCQFINYVKRKMRNDCEYNKVFGLTLLTQYKIEKGENYLEKIYDKETWSKYYILLK
DIDKHIVNAIKDPRYAQSWLYCILNLSVTWRKKNIILSLPRIKLQEIGVYEFEWFSSKNV
FTYSMAELVLNQIKFSLDGVIAYKNRRHLHINIPMSLKISTAIAFIICEIHCREKSKDNI
MYELAQSYIRKSDYKKLFEDDKLLNFENLKCTRSIISYGFSHAINTIGTVPAAYKIYSNR
RSHSDSEQKITNVTGDHYIALDGIENGAKEFMFHVVERGAFGFMYYKLFKCFFDKKDFEN
ISQEQLTDLTKYSDQILNPRTLENIADKFIENDRINKLSIFEILWYSSIIKNKGKRDLSS
KSNIFLAIMIDLYKKQSEDLLGKSDEFKTFVDEKYLQLDAEIEDILKNKISTSKIIDNIL
NGSNCCYSKDTNCIFDRIERKELCPYKYEDNGGKSCVGCKYNLLTVYALNEINEKMQTLL
DKIQKKSYFTKEEIQKNSYILKNYVSIILEASVHFKNEEFLSNYINLKMIKTKIYKLKSE
GKIINI*
>PROKKA_00012 hypothetical protein
VFIISNVIELRNTNSKYRFKVKVCKYKREGRCEDHLFQKAIIVLFDNITGKSRVHEFTEF
AIREFGKNRIKTQVDYLGKLVKFLNYVIKNKDKKNFKYLDFYDVEEFSQEIALDVQMNTF
NIYKMVLSRFYRYLAQKEWLINVSINDFIIKESEKNGGVMIKYDIPICNIDIPNNIHRRN
THVMEYELQAMLLEVAIEEVNIIALAIFFQMFGGLRSGEIVNLTHSAVQCIGPYGRYGML
LDITDRNLRLDLKNNQAKGYSKKSRKQKVISPFNMLEKIYIQHMKKYKCVDDSGAIFVNK
DGMPMTIGSYNYYFDKLKKIFLKRLKESDNPTLKVQGDILCAAKWKTHIGRGIFSNNLGE
FMSASELKIARGDKYINSSDSYIEETKKIGKLYEENAEGAFQLLIKKINE*
>PROKKA_00013 Replication-associated recombination protein A
MSPLADLMRPSKIEDFVGQRHILGKNTPLYNLIKSKKICNCIFYGPPGTGKTTLANIMAK
YVDKKFYKLNATTASVKDIQNITSELDNLLNYAGVVLYIDELC*
>PROKKA_00014 molybdenum cofactor biosynthesis protein MoaC/MOSC-domain-containing protein
MGECIMPTNGVFAKVIEGGQMKIGDEIEIASGIEKMY*
